Study of DispersinB Acne Cleanser for Mild to Moderate Acne
This study is looking at how well and how safely DispersinB Acne Cleanser works for adults with mild to moderate acne on their face. Researchers will compare using DispersinB Acne Cleanser along with 4% Benzoyl Peroxide on one side of your face to using only 4% Benzoyl Peroxide on the other side. To join, you need to be 18 or older and have a specific type of acne (Acne Vulgaris) on your face. The study aims to see how many people have clear or almost clear skin and how much their acne lesions (spots) change after 12 weeks. The study is currently unclear on its recruitment status and plans to enroll 24 participants.
- Study design
- This is a single-center study comparing two treatments on different sides of your face (intra-individual comparison). It plans to include 24 participants.
- What's involved
- You would have a screening period of up to 28 days, then apply the assigned cleansers daily for 12 weeks. You will return to the clinic for assessments at weeks 2, 4, 8, and 12.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be assessed for efficacy and tolerability for 12 weeks after starting treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Prinicipal Investigator · PRINCIPAL_INVESTIGATOR · University of Miami
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Success rate per half-faceBaseline to week 12
Success rate per half-face on the Investigator's Global Assessment - Percent of subjects rated "Clear" and "Almost Clear" on a 5-point scale (0=clear; 4=severe)
- Change in inflammatory and noninflammatory lesion countbaseline to week 12
Change in inflammatory and noninflammatory lesion count per half-face - change in lesion counts equals week 12 count minus baseline count